RVPH

Reviva Pharmaceuticals Holdings, Inc. Common Stock

0.83

USD

RVPH Earnings Reports

Positive Surprise Ratio

RVPH beat 13 of 18 last estimates.

72%

Next Report

Date of Next Report

May 13, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$1.07

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q1 25 (Revenue/ EPS)

-58.85%

Reviva Pharmaceuticals Holdings, Inc. Common Stock earnings per share and revenue

On Mar 23, 2026, RVPH reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -1.19 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.39% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -1.07 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Talphera, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Theravance Biopharma, Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

$1.24

Actual

$0.21

Surprise

-83.12%

Relmada Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.14

Actual

-$0.28

Surprise

-103.08%

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

FAQ

What were Reviva Pharmaceuticals Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Reviva Pharmaceuticals Holdings, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Reviva Pharmaceuticals Holdings, Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -7.39%, changed from $0.89 before the earnings release to $0.83 the day after.

When is Reviva Pharmaceuticals Holdings, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 13, 2026.

What are the forecasts for Reviva Pharmaceuticals Holdings, Inc. Common Stock's next earnings report?

Based on 7 analysts, Reviva Pharmaceuticals Holdings, Inc. Common Stock is expected to report EPS of -$1.07 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.